Once Weekly Basal Insulin

Insulin icodec is the first class of long-acting insulin to be administered only once a week. Join host, Jen Moulton, as she discusses the safety and efficacy of insulin icodec with guest, Geoff Wall.The GameChangerInsulin icodec is the first of the ultra long-acting insulins with once weekly dosing. Multiple clinical studies have suggested these pharmacokinetics work. A new meta-analysis suggests that insulin icodec is more effective than other basal insulins and at least as safe concerning hypoglycemia.Jen Moulton, RPhPresident + FounderCEimpactGeoff Wall, PharmD, BCPS, FCCP, BCGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint Health ReferenceWang P, Zhang Y, Xu W, et al. Efficacy and Safety of Once-Weekly Insulin Regimes on Glycemic Control for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Diabetol Metab Syndr. 2024 Jan 3;16(1):3. doi: 10.1186/s13098-023-01240-5. PMID: 38172995; PMCID: PMC10763463.https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-023-01240-5#Sec19 Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE Information Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Explain the chemical and structural changes that make icodec different from other basal insulins 2. Discuss the results of the meta-analysis about insulin icodec0.05 CEU/0.5 HrUAN: 0107-0000-24-043-H01-PInitial release date: 1/29/2024Expiration date: 1/29/2025Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram